Analyst Expectations for Forward Air’s Future

Forward Air (NASDAQ:FWRD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

Forward Air (NASDAQ:FWRD) has observed the following analyst ratings within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 3 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 1 0 0 0
3M Ago 0 1 0 0 0

In the last 3 months, 4 analysts have offered 12-month price targets for Forward Air. The company has an average price target of $125.5 with a high of $138.00 and a low of $115.00.

Below is a summary of how these 4 analysts rated Forward Air over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has increased by 0.94% from the previous average price target of $124.33.

Stay up to date on Forward Air analyst ratings.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company’s revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC

Read More

Wall Street Analysts Raise Their Oil Price Forecasts After Shocking Supply Cuts By OPEC+

Analysts on Wall Street are becoming far more bullish on oil prices, after OPEC+ announced voluntary output cuts totaling 1.66 million barrel per day. The cuts will come into effect starting in May and are expected to last until the end of 2023.

USO